[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"IRCCS San Raffaele\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":653},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,180,0,25,[9,64,91,113,138,159,179,198,227,254,289,326,348,372,396,416,436,462,489,511,533,558,576,608,633],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":63},"100652437","prospective-perioperative-clinical-registry-for-women-undergoing-benign-gynecological-surgery-100652437",false,"NCT07772076","Prospective Perioperative Clinical Registry for Women Undergoing Benign Gynecological Surgery","Prospective Observational Registry on the Collection of Perioperative Clinical Data in Gynecology","OPGYNBEN","Inclusion Criteria:\n\n1. Age \\>= 18 years\n2. Diagnosis of benign gynecological disease (e.g., uterine fibroids, endometriosis, pelvic neoplasm, endometrial polyp, endometrial hyperplasia, cervical dysplasia, pelvic adhesions, isthmocele, genital prolapse, adenomyosis, female genital malformations, pelvic inflammatory disease)\n3. Indication for elective benign gynecological surgery\n4. Signed written informed consent for data collection\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Suspected or confirmed malignant gynecological disease\n3. Current pregnancy\n4. Emergency \u002F unscheduled surgical procedure\n5. No indication for surgery\n6. Refusal or inability to provide signed informed consent","FEMALE","18 Years",{"count":21,"type":22},6000,"ESTIMATED","3 Years","OBSERVATIONAL","This prospective observational registry aims to systematically collect preoperative, intraoperative, and postoperative clinical data from patients undergoing surgery for benign gynecological conditions. The main goal is to evaluate clinical outcomes, surgical approaches, and complications in real-world clinical practice.",[27,28,29,30,31,32,33,34,35],"Benign Gynecological Disease","Uterine Fibroids","Endometriosis","Adenomyosis","Pelvic Adhesions","Ovarian Cyst Benign","Salpingitis","Polyp Endometrium","Ectopic Pregnancy",[37,38,39,40,41,42,43,44,45,46,47,48,49,50],"Gynecological Surgery","Perioperative Data","Laparoscopy","uterine fibroids","endometriosis","Registry","Uterine Myoma","Pelvic Pain","Surgical Outcomes","Hysteroscopy","Laparotomy","Perioperative Care","Postoperative Complications","Real-World Evidence","NOT_YET_RECRUITING","2026-08-17",{"date":54,"type":55},"2026-08-19","ACTUAL",{"date":57,"type":22},"2026-09",{"date":59,"type":22},"2039-09",{"name":61,"class":62},"IRCCS San Raffaele","OTHER",1,{"id":65,"slug":66,"hasResults":12,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":12,"sex":71,"minAge":19,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100651915","feasibility-of-a-4-week-intensive-postoperative-multimodal-rehabilitation-program-in-complicated-patients-after-proximal-pancreatectomy-a-prospective-single-cohort-study-100651915","NCT07768384","Feasibility of a 4-Week Intensive Postoperative Multimodal Rehabilitation Program in Complicated Patients After Proximal Pancreatectomy: A Prospective Single-Cohort Study","REACT","* Inclusion Criteria:\n* Age ≥18 years.\n* Patients undergoing elective proximal pancreatic resection (pancreatoduodenectomy or total pancreatectomy).\n* Patients developing a severe postoperative complication during their hospital stay, defined as a Comprehensive Complication Index (CCI) \\>21.\n* Exclusion Criteria:\n* Metastatic disease.\n* Surgical procedures other than pancreatoduodenectomy or total pancreatectomy.\n* Inability to speak Italian.\n* Cognitive impairment or illiteracy resulting in inability to read and understand the Italian language.\n* Medical conditions contraindicating the rehabilitation regimen (exercise and nutritional intervention), including orthopedic or cognitive disabilities and chronic renal failure (dialysis or creatinine \\>250 mmol).\n* Pregnancy.","ALL",{"count":73,"type":22},40,"INTERVENTIONAL",[76],"NA","The REACT study is a prospective, single-center, single-cohort study designed to evaluate the feasibility of a 4-week intensive multimodal postoperative rehabilitation program in patients who develop severe complications after proximal pancreatic resection (pancreatoduodenectomy or total pancreatectomy).\n\nPostoperative complications after pancreatic surgery may result in substantial physiological and metabolic stress, leading to loss of muscle mass, malnutrition, reduced functional capacity, and delayed recovery. Although prehabilitation programs have been proposed to improve patients' functional capacity before surgery, evidence regarding structured multimodal rehabilitation after pancreatic surgery is currently lacking.\n\nAdult patients undergoing elective proximal pancreatic resection who develop a severe postoperative complication (Comprehensive Complication Index \\>21) will be eligible for the study. Participants will undergo a 4-week multimodal rehabilitation program starting after hospital discharge and including individualized exercise training, nutritional therapy, and anxiety-reducing techniques. The program may be delivered either in a supervised hospital-based setting or through a home-based program according to patient preference and availability.\n\nThe primary objective is to assess the feasibility of the rehabilitation program in terms of recruitment, adherence, completion of outcome assessments, completeness of data, and safety. Secondary objectives include evaluating postoperative functional recovery using PROMIS-29 Physical and Mental Health Summary Scores, the 6-minute walk test, and the Duke Activity Status Index. In patients with malignancy who are candidates for adjuvant treatment, return to intended oncologic treatment will also be evaluated.\n\nA total of 40 patients will be enrolled and followed for up to 90 days after surgery.",[79],"Pancreatic Diseases",[81,82,83,84,49],"Pancreatic Surgery","Multimodal Rehabilitation","Functional Recovery","Postoperative Rehabilitation","2026-08-14",{"date":52,"type":55},{"date":57,"type":22},{"date":89,"type":22},"2028-03-31",{"name":61,"class":62},{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":71,"minAge":19,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":100,"conditions":101,"keywords":102,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":4},"100651893","targeting-pathogenic-myelopoiesis-in-pancreatic-cancer-100651893","NCT07765316","Targeting Pathogenic Myelopoiesis in Pancreatic Cancer","PaMPa","Inclusion Criteria\n\n* For all participants:\n* Age ≥18 years.\n* Ability and willingness to autonomously provide written informed consent.\n* For the PDAC cohort:\n* Clinical diagnosis of non-metastatic pancreatic ductal adenocarcinoma (PDAC).\n* Treatment-naïve status at the time of blood collection, with no prior chemotherapy, radiotherapy, or immunotherapy for PDAC.\n* Newly diagnosed non-metastatic pancreatic cancer eligible for multimodal treatment.\n* Candidate for standard clinical management at IRCCS Ospedale San Raffaele.\n* For the age-matched control cohort:\n* Patient followed at the Pancreatic Cystic Lesion outpatient clinic of IRCCS Ospedale San Raffaele.\n* Diagnosis of intraductal papillary mucinous neoplasm (IPMN) under surveillance, with no evidence of pancreatic malignancy at the time of enrollment.\n* Age within ±5 years of the corresponding PDAC cohort to allow age-matched comparator analyses.\n* Exclusion Criteria\n* For all participants:\n* Inability to autonomously provide informed consent.\n* For the PDAC cohort:\n* Failure to meet the inclusion criteria for the PDAC cohort.\n* Presence of severe comorbidities that, in the investigator's opinion, may interfere with study participation or interpretation of study results.\n* Previous systemic anti-cancer treatment for PDAC.\n* Use of anti-inflammatory drugs, including NSAIDs or immunomodulators.\n* Events or conditions affecting inflammatory parameters, including acute inflammatory or infectious events such as cholangitis, jaundice, or recent invasive procedures.\n* Hematologic diseases.\n* Clinically significant hematological abnormalities that may interfere with immune profiling analyses, as assessed by the investigator.\n* For the age-matched control cohort:\n* Any acute or chronic inflammatory condition or ongoing infection.\n* Any history of cancer or immunological disorders.",{"count":99,"type":22},100,"This prospective observational study aims to investigate pathogenic myelopoiesis in patients with pancreatic ductal adenocarcinoma (PDAC) and to characterize the systemic immune alterations associated with tumor-related inflammation.\n\nThe study will enroll 50 patients with newly diagnosed, non-metastatic, treatment-naïve PDAC and 50 age-matched control patients with intraductal papillary mucinous neoplasm (IPMN) under surveillance and no evidence of pancreatic malignancy. Control patients will be matched to PDAC patients by age within a range of ±5 years whenever feasible.\n\nA single peripheral blood sample will be collected at baseline from all participants. In PDAC patients, blood collection will be performed before initiation of any anti-tumor treatment. Translational analyses will characterize circulating myeloid cells, progenitor cells, and hematopoietic stem and progenitor cell-related transcriptional programs using high-dimensional flow cytometry and single-cell transcriptomic analyses.\n\nThe primary objective is to identify the molecular drivers of pathogenic myelopoiesis in PDAC by assessing quantitative and qualitative differences between PDAC patients and age-matched controls in circulating myeloid and progenitor cell populations and their transcriptional profiles. The study will specifically explore the hypothesis that IL-1β-associated tumor inflammation contributes to systemic reprogramming of hematopoietic progenitor compartments and promotes myeloid-biased hematopoiesis.\n\nPDAC patients will also be followed clinically for 12 months using data derived from routine clinical practice to explore associations between baseline pathogenic myelopoiesis-related profiles and subsequent clinical outcomes. No follow-up is required for control patients.",[79],[103,104,105,106],"Pancreatic Ductal Adenocarcinoma","Pathogenic Myelopoiesis","Single-Cell Transcriptomics","High-Dimensional Flow Cytometry",{"date":52,"type":55},{"date":109,"type":22},"2026-09-30",{"date":111,"type":22},"2029-12-31",{"name":61,"class":62},{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":71,"minAge":19,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":122,"conditions":123,"keywords":127,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":63},"100651474","innovative-3d-preclinical-models-for-mature-b-cell-malignancies-to-advance-personalized-immuno-and-combination-therapies-100651474","NCT07759661","Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies","IMPACT","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of CLL, SMZL or HCL\n* Participant is willing and able to autonomously give informed consent for participation in the study.\n\nExclusion Criteria:\n\n\\- Participant is unable or unwilling to provide informed consent for participation in the study",{"count":121,"type":22},64,"Adult patients with chronic lymphocytic leukemia (CLL), splenic marginal-zone lymphoma (SMZL) and hairy cell leukemia (HCL) followed at participating clinical sites will be enrolled and undergo sampling of additional amount of blood during the blood draws performed as part of standard clinical care.\n\nThe project aims to develop and validate innovative patient-derived 3D bioprinted models that faithfully reproduce the key microenvironments of lymphoid tissues, enabling a more physiologically relevant study of mature B-cell malignancies.",[124,125,126],"Chronic Lymphocytic Leukemia (CLL)","Splenic Marginal Zone Lymphoma","Hairy Cell Leukemia (HCL)",[128,129],"B-cell malignancies","3D models","2026-08-11",{"date":132,"type":55},"2026-08-13",{"date":134,"type":22},"2026-11",{"date":136,"type":22},"2029-11",{"name":61,"class":62},{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":145,"sex":71,"minAge":19,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":4},"100650111","harnessing-the-immunosuppressive-leukemic-microenvironment-to-engineer-t-cells-with-enhanced-anti-tumor-functionality-100650111","NCT07743047","Harnessing the Immunosuppressive Leukemic Microenvironment to Engineer T Cells With Enhanced Anti-tumor Functionality","SynT","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Written informed consent to the regulation of Hematologic Cancer Biobank (EmaBank) of the San Raffaele Hospital (retrospective patients) and to the present study protocol (prospective patients or hematopoietic stem cell transplant donors harvested in the OSR biobank )\n3. Pregnant or breastfeeding and\u002For women of childbearing potential are eligible\n4. Diagnosis of AML (for patient participants)\n5. Hematopoietic stem cell transplant donors whose samples are stored in the OSR Biobank\n6. Patients or healthy donor should express the HLA allele(s) of interest\n\nExclusion Criteria:\n\n1\\. Inability to provide a written informed consent.",true,{"count":147,"type":22},65,"This is a monocentric, retrospective and prospective study aimed to underline the potential of T-cell receptor (TCR)-mediated Ab recognition from the post transplant setting in acute myeloid leukemia (AML). The study is based on three key biological concepts:\n\n* the essential role of CD4+ T cells in leukemia immunosurveillance,\n* the impact of human leukocyte antigen (HLA) loss or downregulation on immune escape,\n* the ability of leukemic cells to remodel the tumor microenvironment and impair T-cell function.\n\nBy addressing these mechanisms, the study aims to identify novel TCRs and generate next-generation engineered T-cell products with improved anti-leukemic activity. The study will be conducted using samples from healthy donors and patients with AML.\n\nThe Retrospective part will involve samples collected per standard of care from patients already present in the institutional Hematologic Cancer Biobank, while prospective part will regard the use of samples collected during the study protocol from healthy donor and AML patients. Healthy donor peripheral blood samples will be used to isolate tumor-specific TCRs and generate engineered T cells, whereas bone marrow and peripheral blood samples from AML patients will be used to evaluate the anti-tumor activity of the engineered T cells.",[150],"Acute Myeloid Leukemia","2026-08-03",{"date":153,"type":55},"2026-08-06",{"date":155,"type":22},"2026-09-01",{"date":157,"type":22},"2030-12-31",{"name":61,"class":62},{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":71,"minAge":19,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":168,"conditions":169,"keywords":170,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100649932","targeting-irak4-in-chronic-lymphocytic-leukemia-100649932","NCT07741695","Targeting IRAK4 in Chronic Lymphocytic Leukemia","PS-CLL016","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of CLL\n* Participant is willing and able to give informed consent for participation in the study.\n\nExclusion Criteria:\n\n\\- Participant is unable or unwilling to provide informed consent for participation in the study",{"count":167,"type":22},50,"Patients with chronic lymphocytic leukemia (CLL) followed at Strategic Research Program on CLL will be enrolled and undergo sampling of additional amount of blood at the time of standard blood tests. Leukemic B cells and peripheral blood mononuclear cells (PBMC).",[124],[171,172],"chronic lymphocytic leukemia","IRAK4",{"date":174,"type":55},"2026-08-04",{"date":57,"type":22},{"date":177,"type":22},"2027-09",{"name":61,"class":62},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":71,"minAge":4,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":190,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":63},"100650284","preclinical-assessment-of-an-engineered-hmgb1-protein-as-a-novel-companion-therapy-for-muscular-dystrophies-100650284","NCT07745218","Preclinical Assessment of an Engineered HMGB1 Protein as a Novel Companion Therapy for Muscular Dystrophies","HEAL-MD","Inclusion Criteria:\n\n1. Patients affected by LAMA2-related muscular dystrophy (LAMA2-RD) actively enrolled in the LAMA2\\_GUP24002 study.\n2. Patients who have ALREADY SIGNED the informed consent for participation in the LAMA2\\_GUP24002 study, including the separate biobank-specific consent (INSPE BIOBANK CONSENT), with consent provided directly by adult patients or, in the case of minors, by their parents or legal guardians.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Withdrawal of informed consent (to the LAMA2\\_GUP24002 study or to biobanking) prior to laboratory analysis.\n2. Insufficient or degraded biological material (e.g., depleted aliquots; volumes below assay requirements; biopsy not representative of LAMA2-RD muscle).\n3. Re-classification of diagnosis as a non-LAMA2-RD condition after the original enrolment in the LAMA2\\_GUP24002 study.",{"count":7,"type":22},"This is a monocentric, no-profit, retrospective and prospective observational cohort study conducted at IRCCS Ospedale San Raffaele.\n\nThe study does not entail any additional procedures or interventions for participants. Biological samples (including blood\u002Fserum and muscle biopsies) are obtained for a previously approved study (LAMA2\\_GUP24002) and collected under the existing BancaINSpe informed consent.\n\nFor the present study, analyses will be performed on biospecimens already stored or that will be stored at BancaINSpe, using portions of material already collected for the LAMA2\\_GUP24002 protocol.",[189],"LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A)","RECRUITING","2026-07-30",{"date":174,"type":55},{"date":194,"type":22},"2026-08-01",{"date":196,"type":22},"2029-07",{"name":61,"class":62},{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":145,"sex":71,"minAge":206,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":74,"phases":210,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":4},"100648445","telerehabilitation-in-alzheimers-disease-100648445","NCT07722169","Telerehabilitation in Alzheimer's Disease","Home-based Virtual Reality Cognitive Training as an add-on to Telerehabilitation in Alzheimer's Disease: Validation of a Protocol to Slow Down Cognitive Decline and Reduce Caregivers' Burden","VRTAD","Inclusion criteria for patients with Alzheimer's disease (AD):\n\n* Age between 50 and 90 years.\n* Diagnosis of Alzheimer's disease according to established diagnostic criteria.\n* Mini-Mental State Examination (MMSE) score between 18 and 24.\n* Stable pharmacological treatment for at least 3 months before enrolment.\n* Ability and willingness to provide written informed consent.\n\nInclusion criteria for caregivers:\n\n* Age ≥18 years.\n* Availability to assist the patient throughout the study.\n* Ability and willingness to provide written informed consent.\n\nExclusion criteria for patients with Alzheimer's disease (AD):\n\n* Refusal or inability to provide written informed consent.\n* History of psychiatric disorders.\n* Significant cerebrovascular disease.\n* Severe visual or hearing impairment that could interfere with study procedures.\n* Psychosis.\n* Major depressive disorder.\n* Alcohol or substance abuse.\n* Use of psychotropic medications that may interfere with neuropsychological assessment or study treatment.\n* Concurrent participation in another interventional pharmacological clinical trial.\n* Any contraindication to undergoing EEG recording.\n\nExclusion criteria for caregivers:\n\n* Refusal or inability to provide written informed consent.\n* History of psychiatric disorders.\n* Major depressive disorder.\n* Alcohol or substance abuse.\n* Use of psychotropic medications that may interfere with neuropsychological assessment.","50 Years","90 Years",{"count":209,"type":22},48,[76],"Telemedicine has developed rapidly during the COVID-19 pandemic and is now integrated into the clinical practice of many hospitals. Telemedicine offers many advantages, and even after the end of the pandemic, many patients still choose to undergo healthcare visits remotely. However, the rapid expansion of telemedicine may be associated with the risk of providing patients with unvalidated and uncontrolled telehealth solutions, potentially negatively impacting their health.\n\nIn this study, the researchers aim to investigate the effectiveness of remote cognitive training in patients with mild-to-moderate Alzheimer's disease (AD) using tablets equipped with virtual reality-based cognitive exercises. The investigators also aim to evaluate the impact of online supervision of cognitive training by a neuropsychologist and to compare the costs and burden of home-based versus hospital-based cognitive training in patients with AD. This project will define the optimal modalities for cognitive telerehabilitation to ensure validated protocols for the continuity of care in AD.",[213],"Alzheimer",[215,216,217,218,219,220],"cognitive training","telerehabilitation","virtual reality","Alzheimer's disease","Cognitive functions","caregiver",{"date":151,"type":55},{"date":223,"type":22},"2026-10",{"date":225,"type":22},"2029-10",{"name":61,"class":62},{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":145,"sex":71,"minAge":235,"maxAge":19,"enrollmentInfo":236,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":238,"conditions":239,"keywords":241,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":251,"leadSponsor":252,"locationsCount":253},"100649843","tolerogenic-potential-of-hematopoietic-stem-and-progenitor-cells-and-inflammatory-bowel-disease-100649843","NCT07740499","TOLerogenic Potential of Hematopoietic Stem and Progenitor Cells and Inflammatory Bowel Disease","Exploring and Exploiting the TOLerogenic Potential of Hematopoietic Stem and Progenitor Cells to Cure Pediatric Inflammatory Bowel Disease","TOL-IBD","Inclusion Criteria:\n\nFor all groups:\n\n* Written informed consent from parent(s)\u002Flegal guardian(s);\n* Sex: Males and Females;\n* Age: ≥2 years and \\\u003C18 years.\n\nFor study group 1:\n\n\\- Subjects with suspected or confirmed IBD diagnosis.\n\nFor study group 2:\n\n\\- Subjects with rectal bleeding w\u002Fo inflammatory disorders of the gastrointestinal tract.\n\nFor study group 3:\n\n* Written consent for participation to TIGET09 study protocol;\n* healthy subjects, without known immunodeficiencies, autoimmune, inflammatory or genetic diseases, undergoing genetic, hematological, hematochemical, or HLA compatibility screenings and participating in the TIGET09 study protocol (Title: \"Collection of biological samples for the study of blood cells and their microenvironment, and for the development of novel therapeutic approaches for genetic diseases and cancer\").\n\nExclusion Criteria:\n\nFor all groups:\n\n* Refusal or inability of the parent(s) or legal guardian(s) to provide written informed consent;\n* Age: \\\u003C2 years and ≥18 years;\n* Presence of any medical, psychiatric, or clinical condition that, in the opinion of the clinician, may interfere with participation in the study or interpretation of the study results;\n\nFor study group 1:\n\n\\- patients without IBD diagnosis or suspect;\n\nFor study group 2:\n\n\\- Subjects without rectal bleeding or with known inflammatory\u002Fautoimmune disorders of the gastrointestinal tract.\n\nFor all groups:\n\n* Refusal or inability of the parent(s) or legal guardian(s) to provide written informed consent;\n* Age: \\\u003C2 years and ≥18 years;\n* Presence of any medical, psychiatric, or clinical condition that, in the opinion of the clinician, may interfere with participation in the study or interpretation of the study results;\n\nFor study group 1:\n\n\\- patients without IBD diagnosis or suspect;\n\nFor study group 2:\n\n\\- Subjects without rectal bleeding or with known inflammatory\u002Fautoimmune disorders of the gastrointestinal tract.\n\nFor study group 3:\n\n* Lack of written consent for participation to TIGET09 study protocol;\n* patients belonging to study groups 1 and 2; patients with immunodeficiencies, autoimmune, inflammatory or genetic diseases;\n* subjects with signs of systemic inflammation.","2 Years",{"count":237,"type":22},80,"Pediatric refractory Inflammatory Bowel Disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract, not responsive to current treatments. Since hematopoietic stem and progenitor cells (HSPCs) in the bone marrow display immunomodulatory functions and IL-10-producing regulatory cells regulate gut homeostasis, by combining state-of-the-art strategies for the ex-vivo manipulation and expansion of HSPCs and gene delivery systems to drive HLA-class II-restricted antigen presentation and expression of tolerogenic molecules, the investigators propose to dissect the antigen- (Ag-) presenting capacity of HSPCs and to exploit their tolerogenic potential to induce IL-10-mediated tolerance in the intestinal mucosa of IBD patients. The investigators hypothesize that HSPCs can be engineered using commensal-derived Ags w\u002Fwo IL-10 to drive the differentiation of Tr1 cells with the desired Ag-specificity to control intestinal inflammation in IBD. The results of this study will pave the way for defining innovative cell-based approaches for treating refractory pediatric IBD.",[240],"Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)",[242,243,244,245,246],"hematopoietic stem and progenitor cells (HSPCs)","immune tolerance","regulatory T cells","IL-10 producing cells","commensal-derived epitopes","2026-07-28",{"date":249,"type":55},"2026-07-31",{"date":223,"type":22},{"date":136,"type":22},{"name":61,"class":62},2,{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":145,"sex":71,"minAge":19,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":264,"conditions":265,"keywords":271,"overallStatus":190,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":63},"100648193","optical-coherence-tomography-in-neurological-practice-utility-and-applicability-across-neurological-diseases-octinn-100648193","NCT07720765","Optical Coherence Tomography in Neurological Practice: Utility and Applicability Across Neurological Diseases (OCt.IN.N)","A National, Monocentric, Prospective Cohort Study to Evaluate the Utility and Applicability of Optical Coherence Tomography in Neurological Clinical Practice","OCT","Inclusion Criteria for neurological patients:\n\n1. Diagnosis of a Central Nervous System neurological disease (inflammatory diseases such as Multiple Sclerosis; neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease; migraine\u002Fheadache) according to currently accepted diagnostic criteria for each condition.\n2. Age greater than 18 years.\n3. Signed informed consent to study participation.\n4. Willingness and ability to undergo all study visits and procedures.\n\nInclusion Criteria for healthy controls:\n\n1. Absence of neurological disease.\n2. Age greater than 18 years.\n3. Signed informed consent to study participation.\n4. Willingness and ability to undergo all study visits and procedures.\n\nExclusion Criteria for neurological patients:\n\n1. Refusal to participate or withdrawal of informed consent.\n2. Known or confirmed ocular pathology identified during examination (ophthalmological evaluation may be requested at the investigators' discretion).\n3. Inability to understand instructions given by investigators.\n4. Presence of any condition that, in the investigators' opinion, renders the subject unsuitable for the study.\n5. For specific imaging modes using clearly visible light sources (MultiColor, FA, BAF): diagnosis of epilepsy or history of previous epileptic seizures.\n\nExclusion Criteria for healthy controls:\n\n1. Refusal to participate or withdrawal of informed consent.\n2. Known or confirmed ocular pathology identified during examination.\n3. Inability to understand instructions given by investigators.\n4. Presence of any condition that, in the investigators' opinion, renders the subject unsuitable for the study.",{"count":263,"type":22},1050,"OCt.IN.N is a national, monocentric, prospective, observational cohort study evaluating the utility and applicability of Optical Coherence Tomography (OCT) in the diagnostic workup and longitudinal monitoring of neurological diseases.\n\n840 patients with Central Nervous System neurological diseases (Multiple Sclerosis, Alzheimer's disease, Parkinson's disease, migraine\u002Fheadache) and 210 age-matched healthy controls will undergo OCT examination at baseline and at 6, 12, 18, and 24 months of follow-up at IRCCS San Raffaele Hospital, Milan, Italy.\n\nOCT is a non-invasive, rapid, and reproducible technique that automatically measures the thickness of individual retinal layers. Retinal layer thicknesses and their longitudinal changes will be correlated with established clinical scales, neuroimaging, and biological markers used in routine neurological practice.",[266,267,268,269,270],"Multiple Sclerosis","Alzheimer Disease","Parkinson Disease","Migraine","Headache Disorders",[272,260,273,274,275,276,266,218,277,269,278,279,280],"Optical Coherence Tomography","Retinal nerve fiber layer","RNFL","Ganglion cell layer","GCL","Parkinson's disease","Neurodegeneration","Neuro-retina","Biomarker","2026-07-17",{"date":283,"type":55},"2026-07-22",{"date":285,"type":55},"2023-10-09",{"date":287,"type":22},"2031-04-01",{"name":61,"class":62},{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":71,"minAge":297,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":300,"conditions":301,"keywords":306,"overallStatus":190,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":63},"100648037","blood-tests-for-alzheimers-disease-can-plasma-biomarkers-diagnose-and-predict-disease-progression-100648037","NCT07717567","Blood Tests for Alzheimer's Disease: Can Plasma Biomarkers Diagnose and Predict Disease Progression","The Diagnostic and Prognostic Role of Plasma Biomarkers in Alzheimer's Disease","BLAD","Inclusion Criteria (main study and sub-study):\n\n1. Age greater than or equal to 40 years (patients of childbearing age are admitted).\n2. Subjective or objective cognitive complaints, progressive in nature and of suspected neurodegenerative origin.\n3. Mini-Mental State Examination (MMSE) score greater than or equal to 18.\n\n   Additional inclusion criterion for the validation sub-study:\n4. Availability of CSF biomarkers for Alzheimer's disease within 6 months of the blood draw.\n\nExclusion Criteria (main study):\n\n1. Secondary forms of cognitive impairment based on medical history, neurological examination, and neuroimaging findings.\n2. Pregnancy or breastfeeding.\n3. Rapidly progressive cognitive decline occurring over weeks or months, typically indicative of prion disease, neoplasia, or metabolic disorders.\n4. Subjects who require a legal guardian or tutor.\n\nExclusion Criteria (validation sub-study):\n\n1. Secondary forms of cognitive impairment based on medical history, neurological examination, and neuroimaging findings.\n2. Pregnancy.\n3. Rapidly progressive cognitive decline occurring over weeks or months, typically indicative of prion disease, neoplasia, or metabolic disorders.\n4. Subjects who are unable to give informed consent and require a legal guardian or tutor.","40 Years",{"count":299,"type":22},2000,"BLAD is a prospective, monocentric, observational epidemiological study with an additional procedure (annual blood draw) evaluating the diagnostic and prognostic performance of plasma biomarkers for Alzheimer's disease (AD) in a large cohort of patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital, Milan, Italy.\n\n2000 patients will be enrolled and followed annually for 5 years. A validation sub-study (150 patients) will compare plasma biomarkers against CSF biomarkers as the gold standard.\n\nThe study aims to establish plasma biomarkers as a less invasive and more cost-effective alternative to CSF analysis and amyloid-PET for the diagnosis and prognosis of AD.",[267,302,303,304,305],"Mild Cognitive Impairment","Subjective Cognitive Decline","Dementia","Cognitive Impairment",[218,307,308,309,310,311,312,313,314,302,303,304,315,316,317],"Plasma biomarkers","pTau-181","Abeta42","Abeta40","NfL","GFAP","sTREM2","ApoE","Blood biomarkers","Diagnostic accuracy","Prognosis","2026-07-16",{"date":320,"type":55},"2026-07-21",{"date":322,"type":55},"2023-09-12",{"date":324,"type":22},"2032-06-01",{"name":61,"class":62},{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":71,"minAge":19,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":334,"conditions":335,"keywords":337,"overallStatus":190,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":63},"100647112","san-raffaele-registry-on-liver-cancer-100647112","NCT07704489","San Raffaele Registry on Liver Cancer","Inclusion Criteria:\n\n1. Participant is willing and able to give informed consent for participation in the study. However, concerning the retrospective cohort, the large sample sizes needed and considering that the disease involved in this study affects elderly subjects with co-morbidities and presents a significant mortality rate based on the stage of the disease, deceased and untraceable patients will also be included.\n2. ≥18 years of age.\n3. Patients diagnosed with any subtype of biliary tract cancer (i.e. iCCA, pCCA, dCCA or GBC) at every stage and with all therapeutic indications.\n4. Patients diagnosed with hepatocellular carcinoma at every stage and treated with all therapeutic options.\n\nExclusion Criteria:\n\n1\\. Patients without diagnosis of hepatocellular carcinoma or biliary tract cancer (BTC).",{"count":333,"type":22},4000,"This is a Retrospective and Prospective Observational Single-Center Study. The purpose is to collect all data to generate a registry of primary liver cancer (hepatocellular carcinoma and biliary tract carcinoma) of patients accessing to San Raffaele Hospital. An additional purpose is to identify novel biomarkers to better manage primary liver cancer patients, for whom additional biological samples will be collected.\n\nA total of 4000 patients will be enrolled; for the prospective cohort: from protocol approval to the achievement of the last planned patients in the prospective cohort (2000 patients). The retrospective cohort will start from the year 2000.\n\nPatients will be followed for 5 years of follow-up.",[336],"Liver and Intrahepatic Biliary Tract Cancer",[338,339],"registry of primary liver cancer","hepatocellular carcinoma and biliary tract carcinom","2026-07-14",{"date":342,"type":55},"2026-07-15",{"date":344,"type":55},"2021-10-20",{"date":346,"type":22},"2050-10",{"name":61,"class":62},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":71,"minAge":19,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":357,"conditions":358,"keywords":361,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":368,"completionDateStruct":369,"leadSponsor":371,"locationsCount":63},"100645697","targeting-glut1-to-control-autoimmunity-in-type-1-diabetes-100645697","NCT07695727","Targeting GLUT1 to Control Autoimmunity in Type 1 Diabetes","GLUT1D","Inclusion Criteria:\n\n* PBMC samples obtained from adult subjects aged 18 years or older at the time of sample collection.\n* Documented diagnosis of Type 1 Diabetes.\n* PBMC samples already collected and stored in the institutional Biobank of IRCCS Ospedale San Raffaele.\n* PBMC samples obtained from subjects who had previously provided written informed consent for the collection, storage, and research use of biological material and associated data.\n\nExclusion Criteria:\n\n* PBMC samples obtained from subjects younger than 18 years at the time of sample collection.\n* Presence of relevant concomitant diseases or clinical conditions that, in the Investigator's judgment and based on available records, may interfere with the interpretation of immunological analyses or with the study objectives.\n* Insufficient sample availability, inadequate sample quality, or missing essential sample-related information preventing use of the PBMC sample for the planned research activities.",{"count":356,"type":22},84,"Type 1 Diabetes is an autoimmune disease in which immune cells contribute to the destruction of insulin-producing pancreatic beta cells. This study investigates whether targeting glucose transporter 1 (GLUT1), a transporter involved in immune cell metabolism, may help modulate autoimmune responses associated with Type 1 Diabetes.\n\nThe study uses previously collected and biobanked peripheral blood mononuclear cells (PBMCs) from individuals with Type 1 Diabetes. No additional visits, blood draws, or study-specific procedures will be performed on human participants.",[359,360],"Type 1 Diabetes","Autoimmunity",[360,359,362,363,364,365],"GLUT1","Humanized mice","Immunometabolism","T cells","2026-07-10",{"date":340,"type":55},{"date":57,"type":22},{"date":370,"type":22},"2029-09",{"name":61,"class":62},{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":71,"minAge":4,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":390,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":63},"100645432","clinical-predictors-of-visual-outcome-in-patients-affected-with-ocular-surface-diseases-100645432","NCT07694817","Clinical Predictors of Visual Outcome in Patients Affected With Ocular Surface Diseases","Clinical Predictors of Visual Outcome in Patients Affected With Ocular Surface Diseases: Single Center Retrospective-prospective Clinical Study","OSD","Inclusion Criteria:\n\n* The participant is willing and able to provide written informed consent for study participation (prospective cohort).\n* Adult participants aged ≥18 years at the time of inclusion.\n* Clinically confirmed diagnosis of OSD, including but not limited to inflammatory keratopathies, neurotrophic keratopathy, exposure keratopathy, limbal stem cell deficiency, post-surgical or post-traumatic corneal alterations.\n* Measurable BSCVA obtained through standardized manifest refraction and ETDRS chart testing at baseline.\n* Available dataset for the diagnostic tests required by the study (e.g., corneal topography, pachymetry, confocal microscopy, corneal sensitivity testing, slit-lamp imaging, tear cytokine analysis, impression cytology).\n* Willingness and ability to attend follow-up visits and complete all study-related procedures according to the study schedule.\n\nExclusion Criteria:\n\n* Change of retinal, optic nerve, or macular pathology that may affect best spectacle-corrected visual acuity independently of the cornea or ocular surface (e.g., age-related macular degeneration, diabetic macular edema, optic neuropathy) in the period of study\n* History of intraocular or corneal surgery within 3 months prior to baseline evaluation.\n* Active intraocular inflammation, glaucoma with uncontrolled intraocular pressure, or corneal conditions not compatible with accurate imaging or measurement (e.g., severe scarring, leukoma).\n* Uncontrolled systemic diseases that may impair vision or corneal health (e.g., advanced diabetes, autoimmune disease in active phase).\n* Inability or unwillingness to attend follow-up visits or complete study assessments.\n* Pregnant or breastfeeding women will not be enrolled, as hormonal fluctuations can alter tear film and ocular surface physiology",{"count":381,"type":22},1000,"This retrospective-prospective study aims to identify the diagnostic parameters most predictive of BSCVA in patients with OSD. Clinical, structural, and biochemical data will be collected from standard-of-care examinations and patient-reported outcome questionnaires. The goal is to determine the most informative biomarkers for visual prognosis, streamline diagnostic workflows, and support individualized management of OSD.",[384,385,386,387,388,389],"Neurotrophic Keratopathy","Exposure Keratopathy","Limbal Stem Cell Deficiency (LSCD)","Cornea Abnormality","Cornea Disease","Cornea Inflamed",{"date":340,"type":55},{"date":392,"type":22},"2026-07",{"date":394,"type":22},"2029-12",{"name":61,"class":62},{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":403,"minAge":19,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":74,"phases":406,"briefSummary":407,"conditions":408,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":413,"leadSponsor":415,"locationsCount":63},"100645455","use-of-a-virtual-reality-headset-during-prostate-biopsy-under-local-anesthesia-to-improve-the-patients-experience-100645455","NCT07701421","Use of a Virtual Reality Headset During Prostate Biopsy Under Local Anesthesia to Improve the Patient's Experience","Use of a Virtual Reality Visor (REALICA®) as an Supplementary Tool to Local Anesthesia in Patients Undergoing Prostate Biopsy: A Randomized Clinical Trial","Inclusion Criteria:\n\n* The participant provides written informed consent for the trial\n* Male participants who are at least 18 years of age on the day of signing informed consent\n* Men undergoing transperineal prostate biopsy under local anesthesia\n\nExclusion Criteria:\n\n* Visual or hearing impairment that would prevent effective use of the virtual reality device\n* History of epilepsy or seizure disorders\n* Severe motion sickness or known susceptibility to cybersickness\n* Severe psychiatric disorders that, in the investigator's judgment, could interfere with study participation or outcome assessment","MALE",{"count":405,"type":22},200,[76],"This is a post-market clinical investigation evaluating the effect of immersive virtual reality (VR) as an adjunct to standard local anesthesia during transperineal prostate biopsy.\n\nTransperineal prostate biopsy under local anesthesia is commonly associated with patient anxiety, procedural discomfort, and vasovagal reactions, which may negatively impact patient experience and procedural tolerability. Non-pharmacological distraction techniques such as immersive VR have shown potential to reduce perceived pain and anxiety during short, invasive medical procedures by modulating cognitive attention and emotional response.\n\nThis study investigates whether the use of an immersive VR headset, added to standard local anesthesia, can reduce peri-procedural anxiety and pain compared to standard care alone. The intervention is designed to provide continuous audiovisual immersive distraction starting shortly before the procedure and continuing throughout the biopsy, without altering standard clinical workflow or increasing procedural invasiveness.\n\nThis is a randomized, controlled, parallel-group, 1:1 superiority trial with a single-blind (assessor-blinded) design. Participants undergoing transperineal prostate biopsy under local anesthesia will be randomly assigned to one of two groups: standard local anesthesia alone (control arm) or standard local anesthesia plus immersive VR (experimental arm).\n\nThe primary objective is to evaluate whether immersive VR reduces peri-procedural anxiety and pain compared with standard local anesthesia alone. Secondary objectives may include evaluation of patient satisfaction, tolerability of the VR intervention, and incidence of vasovagal reactions or procedural interruptions.\n\nThe study aims to generate evidence on the feasibility and clinical benefit of integrating immersive VR as a non-pharmacological supportive tool in urological diagnostic procedures.",[409],"Prostate Biopsy","2026-07-08",{"date":340,"type":55},{"date":57,"type":22},{"date":414,"type":22},"2028-10",{"name":61,"class":62},{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":145,"sex":71,"minAge":19,"maxAge":423,"enrollmentInfo":424,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":425,"conditions":426,"keywords":4,"overallStatus":190,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":63},"100629320","quantifying-gait-disorders-with-wearable-sensors-100629320","NCT07473141","Quantifying Gait Disorders With Wearable Sensors","Quantification of Gait Differences Between Healthy Volunteers and Patients Suffering From Gait Disorders Through Wearable Sensors","Inclusion Criteria:\n\n* Hospitalized at the Department of Rehabilitation and Functional Recovery of IRCCS Ospedale San Raffaele - Milan (during the hospitalization period)\n* Ability to understand and sign informed consent\n* ≥ 18 years ≤80 years\n* Male and female\n* Presence of clinically diagnosed gait impairments\n* No skin conditions or allergies preventing sensor application\n\nExclusion Criteria:\n\n* Cognitive impairment interfering with task comprehension\n* Cardiorespiratory instability or other contraindications to walking assessment","80 Years",{"count":99,"type":22},"This is a single-centre, cross-sectional observational study with adjunctive procedure for the healthy voluteers at IRCCS Ospedale San Raffaele's Rehabilitation Department.\n\nPatients (n=50): use of inertial measurement units (IMU) and electromyographic (EMG) data routinely acquired during their standard clinical gait-rehabilitation sessions (no protocol changes; purely observational, data extracted from treatments).\n\nHealthy volunteers (n=50): age- and sex-matched volunteers who complete three 18 meters gait sessions with IMUs on trunk, thighs, shanks and feet and surface EMG on gluteus, quadriceps, hamstrings, tibialis anterior, and gastrocnemius. Healthy volunteers will be enrolled from hospital personnel, family members of the patients in visit at San Raffaele Hospital.\n\nData \\& Analysis: Kinematic (range of motion - ROM, step timing, walking speed) and EMG (activation amplitude\u002Ftiming) parameters will be extracted. Between-group comparisons will employ t-tests\u002Fanalysis of variance - ANOVA - (or non-parametric equivalents).",[427],"Gait Disorders","2026-07-07",{"date":430,"type":55},"2026-07-09",{"date":432,"type":55},"2026-03-02",{"date":434,"type":22},"2028-01-08",{"name":61,"class":62},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":18,"minAge":443,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":74,"phases":446,"briefSummary":447,"conditions":448,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":459,"leadSponsor":461,"locationsCount":63},"100645930","effect-of-egcg-folic-acid-vitamin-b12-and-hyaluronic-acid-on-hpv-dna-integration-100645930","NCT07697196","Effect of EGCG, Folic Acid, Vitamin B12 and Hyaluronic Acid on HPV DNA Integration","An Interventional Study Evaluating the Effect of Epigallocatechin Gallate (EGCG), Folic Acid (FA), Vitamin B12 (B12) and Hyaluronic Acid (HA) in Affecting the DNA Integration of Human Papilloma Virus (HPV) in Women With Persistent Infection","Inclusion Criteria:\n\n1. Age ≥ 25 years old\n2. Positive HPV DNA test with genotyping 9-24 months prior to Day 0\n3. Positive HPV DNA test with genotyping at Day 0\n4. Presence of an HPV-related cervical lesion within 5-24 months prior to Day 0. This lesion will be defined alternatively as:\n\n   1. Pap test: LSIL, ASC-US.\n   2. Colposcopic impression suggestive of a low-grade lesion.\n   3. Histologic report of a colposcopic biopsy consistent with a low-grade lesion.\n5. Previous HPV vaccination (latest dose at least 24 months earlier than Day 0)\n6. Patients able to accept and sign informed consent for the study\n7. Patients able to adhere to the proposed study protocol\n\nExclusion Criteria:\n\n1. High grade cervical lesions (HSIL)\n2. Ongoing pregnancy, evaluated through a rapid chromatographic immunoassay for qualitative detection of hCG in urine\n3. Ongoing breastfeeding\n4. Primary or secondary immunodepression due to pharmacological treatments\n5. No HPV vaccination\n6. Daily assumption of other products containing green tea\n7. Hypersensitivity or allergy to the substances contained in the supplement","25 Years",{"count":445,"type":22},42,[76],"This interventional, single-center, open-label randomized clinical study evaluates the efficacy of an oral dietary supplement (Pervistop®) in women with persistent Human Papillomavirus (HPV) infection. The supplement is a combination of four natural molecules: Epigallocatechin gallate (EGCG), folic acid (FA), vitamin B12 (B12), and hyaluronic acid (HA).The primary objective is to describe the effect of this association on HPV DNA integration into the host genome by measuring the clearance rate of viral oncoproteins E6 and E7. A total of 42 women aged 25 or older with persistent HPV infection and low-grade cervical lesions will be randomized 1:1 into two groups. The treated group will receive one tablet of Pervistop® daily for six months, while the control group will follow standard clinical practice. The study aims to determine if this nutritional intervention can counteract viral persistence.",[449,450,451,452,453,454],"HPV Infection","HPV Integration","HPV Disease","HPV Genital Infection","HPV Persistence","Low Grade Squamous Intraepithelial Lesions of the Cervix","2026-07-06",{"date":457,"type":55},"2026-07-13",{"date":392,"type":22},{"date":460,"type":22},"2028-06",{"name":61,"class":62},{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":145,"sex":71,"minAge":19,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":471,"conditions":472,"keywords":478,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":486,"leadSponsor":488,"locationsCount":4},"100645202","ai-technologies-for-enhanced-and-celerated-high-field-wb-mri-100645202","NCT07678320","AI Technologies for Enhanced and Celerated High-Field WB-MRI","AITECH-MRI","Inclusion Criteria:\n\n* Consecutive adults (≥18 y.o.) admitted to the UO for W MRI for screening procedure.\n* Consecutive adult male patients (≥18 y.o.) admitted to the UO for WB-MRI for screening procedure and focus on prostate.\n\nExclusion Criteria:\n\n* refused to consent\n* claustrophobia\n* metal prosthesis potentially affecting image quality",{"count":470,"type":22},600,"Single-center, cross-sectional observational study assessing the feasibility of advanced accelerated MRI sequences versus standard ones in terms of image quality, diagnostic reliability, and acquisition time.",[473,474,475,476,477],"Whole Body Imaging","Prostate","MRI","Lung","Vascular",[475,479,480,481,477],"Whole Body","Accelerated Imaging","Prostate Imaging","2026-06-25",{"date":484,"type":55},"2026-07-01",{"date":484,"type":22},{"date":487,"type":22},"2029-05-01",{"name":61,"class":62},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":71,"minAge":19,"maxAge":497,"enrollmentInfo":498,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":500,"conditions":501,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":4},"100644776","sterify-gel-as-an-adjunct-to-non-surgical-periodontal-therapy-in-periodontitis-100644776","NCT07672665","Sterify Gel as an Adjunct to Non-Surgical Periodontal Therapy in Periodontitis","The Adjunctive Effect of a Mucoadhesive Polymeric Hydrogel to Non-surgical Periodontal Therapy: a Retrospective Analysis","Sterify","Inclusion Criteria:\n\n* Adult patients aged \\>18 years\n* Diagnosis of stage II, III, or IV periodontitis\n* Non-smokers\n* Negative medical history\n* Patients treated with scaling and root planing\u002Fminimally invasive non-surgical periodontal therapy plus mucoadhesive polymeric hydrogel\n* Patients enrolled in supportive periodontal care\n\nExclusion Criteria:\n\n* Smokers\n* Pregnancy\n* Surgical re-treatment during the maintenance period","100 Years",{"count":499,"type":22},20,"This retrospective observational study will evaluate the clinical response to Sterify Gel, a sterile mucoadhesive polymeric hydrogel, when used as an adjunct to non-surgical periodontal therapy in adult patients with stage II, III, or IV periodontitis.\n\nThe study will analyze already existing anonymized clinical records from patients treated at the Periodontal Unit of IRCCS Ospedale San Raffaele in Milan, Italy. Patients included in the analysis received scaling and root planing\u002Fminimally invasive non-surgical periodontal therapy, followed by local application of Sterify Gel into periodontal pockets with probing depth greater than 4 mm.\n\nThe main objective is to assess reduction in periodontal pocket depth from baseline to 6, 12, and 24 weeks. Other periodontal clinical parameters, including clinical attachment level, gingival recession, bleeding, plaque score, tooth mobility, and furcation involvement, will also be evaluated.",[502],"Periodontitis","2026-06-22",{"date":505,"type":55},"2026-06-29",{"date":507,"type":22},"2026-06",{"date":509,"type":22},"2026-12",{"name":61,"class":62},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":145,"sex":71,"minAge":19,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":520,"conditions":521,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":529,"completionDateStruct":530,"leadSponsor":532,"locationsCount":4},"100644024","effects-of-chlorhexidine-on-human-gingival-fibroblasts-100644024","NCT07669636","Effects of Chlorhexidine on Human Gingival Fibroblasts","In Vitro Effects of a New Chlorhexidine-based Solution on Human Gingival Fibroblasts Survival and Function","Inclusion Criteria:\n\n* Male or female adults aged 18 years or older.\n* Undergoing routine dental surgical procedures (e.g., tooth extraction or gingivectomy).\n* Willing and able to provide written informed consent for the use of discarded gingival tissue for research purposes.\n* Systemically healthy.\n\nExclusion Criteria:\n\n* Presence of systemic diseases.\n* Presence of relevant medical comorbidities.\n* Current smoker.\n* Refusal to provide informed consent for the use of discarded biological material.",{"count":519,"type":22},3,"This prospective in vitro study aims to evaluate the effects of two chlorhexidine-based mouthwash formulations on the survival and function of human gingival fibroblasts (hGFs). Gingival fibroblasts obtained from discarded gingival tissue collected during routine dental procedures will be cultured and exposed to different concentrations of a conventional 0.2% chlorhexidine mouthwash and a 0.2% chlorhexidine mouthwash supplemented with N-acetylcysteine (NAC) and hyaluronic acid (HA).\n\nCell viability, apoptosis, migration, and gene expression will be assessed at multiple time points using Trypan Blue exclusion assay, fluorescence-activated cell sorting (FACS), scratch assay, and quantitative real-time PCR. The study is designed to investigate the concentration-dependent effects of chlorhexidine on fibroblast viability and wound-healing-related functions and to determine whether the addition of NAC and HA may improve the biological compatibility of chlorhexidine-based formulations.",[522,523,524,525,526],"HGF","Fibroblast","Chlorhexidine","Cytotoxicity","Biocompatibility","2026-06-20",{"date":482,"type":55},{"date":484,"type":22},{"date":531,"type":22},"2026-11-01",{"name":61,"class":62},{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":539,"eligibilityCriteria":540,"healthyVolunteers":145,"sex":71,"minAge":541,"maxAge":542,"enrollmentInfo":543,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":545,"conditions":546,"keywords":547,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":554,"leadSponsor":556,"locationsCount":557},"100644572","m1no-study---early-identification-of-infants-with-high-type-1-diabetes-risk-for-participation-in-primary-prevention-trials-100644572","NCT07670143","M1no-Study - Early Identification of Infants With High Type 1 Diabetes Risk for Participation in Primary Prevention Trials","Identification of Infants With Increased Type 1 Diabetes Risk for Enrollment Into Primary Prevention Trials.","M1N0","Inclusion Criteria:\n\n* Screening is performed between the ages of 0 and 6 weeks.\n* Consent form signed by parents\u002Fguardian.\n\nExclusion Criteria:\n\n* Infants aged above 6 weeks.\n* Refusal to participate in the study","0 Weeks","6 Weeks",{"count":544,"type":22},50000,"The goal of this observational study is to identify newborns at increased genetic risk of developing type 1 diabetes-specific beta-cell autoantibodies in order to determine eligibility for participation in primary prevention randomized controlled trials aimed at preventing beta-cell autoimmunity.",[359],[359,548,549,539],"Genetic Testing","Infants","2026-06-18",{"date":552,"type":55},"2026-06-26",{"date":392,"type":22},{"date":555,"type":22},"2031-06",{"name":61,"class":62},5,{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":71,"minAge":19,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":573,"leadSponsor":575,"locationsCount":4},"100644374","monocentric-retrospective-and-prospective-observational-study-of-patients-with-colorectal-cancer-100644374","NCT07663162","Monocentric Retrospective and Prospective Observational Study of Patients With Colorectal Cancer","CRC-R","Inclusion Criteria:\n\n1. Participant is willing and able to give informed and written consent for the participation in the study\n2. Patients affected by colorectal neoplasm (regardless of disease stage)\n3. Aged \\> 18 years\n4. Patients in clinical conditions permissive to adhere to the diagnostic-therapeutic program proposed in according to the stage of the disease\n\nExclusion Criteria:\n\n1. Pediatric population\n2. Pre-existing conditions or concurrent diagnoses that would preclude the participant's full adherence with or completion of the study\n3. Pregnancy",{"count":299,"type":22},"Monocentric retrospective and prospective observational study of patients with colorectal cancer",[568],"CRC (Colorectal Cancer)","2026-06-16",{"date":571,"type":55},"2026-06-23",{"date":507,"type":22},{"date":574,"type":22},"2036-06",{"name":61,"class":62},{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":582,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":71,"minAge":297,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":74,"phases":586,"briefSummary":587,"conditions":588,"keywords":590,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":604,"completionDateStruct":605,"leadSponsor":607,"locationsCount":63},"100642364","using-artificial-intelligence-to-detect-early-signs-of-alzheimers-disease-in-people-with-memory-concerns-100642364","NCT07652931","Using Artificial Intelligence to Detect Early Signs of Alzheimer's Disease in People With Memory Concerns","AHEAD: AI-driven Brain Health for Early Alzheimer's Disease Detection in Individuals With Subjective Cognitive Decline","AHEAD","Inclusion Criteria:\n\n1. Diagnosis of Subjective Cognitive Decline (SCD) according to international diagnostic criteria (Jessen et al., 2014).\n2. Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event.\n3. Normal age-, gender-, and education-adjusted performance on standardized cognitive tests used to classify mild cognitive impairment (MCI) or prodromal AD.\n4. Age greater than or equal to 40 years.\n5. Native Italian Speaker.\n6. Stable pharmacological treatment for at least 4 weeks prior to enrollment.\n7. Provision of oral and written informed consent to study participation.\n\nExclusion Criteria:\n\n1. Presence of MCI, prodromal AD, or dementia.\n2. Any major systemic, psychiatric, or neurological disturbance.\n3. Medical conditions or substance abuse that could interfere with cognition.\n4. Pacemaker and\u002For other implanted neurostimulation devices in the head\u002Fneck district.\n5. Contraindications to undergoing MRI examination.\n6. Brain damage at routine MRI, including extensive cerebrovascular disorders.\n7. Traumatic or surgical wounds that could determine a risk of infection at the site of non-invasive stimulation.\n8. Scalp alterations that could determine the spread of excessive current from the device.\n9. Known history of epilepsy (due to small risk of seizure induction from rTMS in epileptic patients).\n10. Denial of oral and written informed consent to study participation.",{"count":585,"type":22},300,[76],"AHEAD is a prospective, longitudinal, risk-stratified single-arm interventional study enrolling 300 patients with Subjective Cognitive Decline (SCD) at IRCCS San Raffaele Hospital, Milan, Italy.\n\nThe study uses artificial intelligence (AI) to integrate multimodal data - including MRI, EEG, Optical Coherence Tomography (OCT), neuropsychological assessments, and plasma biomarkers - to identify individuals with underlying Alzheimer's disease (AD) biology and predict cognitive progression.\n\nOnly participants found to be AD plasma biomarker positive (SCD+) undergo longitudinal follow-up at 12 and 24 months. Participants classified as high risk additionally receive a 6-month personalized multidisciplinary intervention combining high-frequency transcranial magnetic stimulation (TMS), digital cognitive training, structured physical exercise, and targeted management of modifiable vascular and behavioral risk factors.",[303,267,302,589],"Cognitive Decline",[303,218,591,592,307,593,475,594,272,595,596,597,598,599,600],"Artificial Intelligence","Transcranial Magnetic Stimulation","p-tau217","EEG","Cognitive Training","Physical Exercise","Brain Health","APOE","Machine Learning","Deep Learning","2026-06-11",{"date":603,"type":55},"2026-06-17",{"date":194,"type":22},{"date":606,"type":22},"2029-08-01",{"name":61,"class":62},{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":12,"sex":71,"minAge":19,"maxAge":4,"enrollmentInfo":616,"targetDuration":617,"studyType":24,"phases":4,"briefSummary":618,"conditions":619,"keywords":621,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":630,"leadSponsor":632,"locationsCount":4},"100643399","hydrocortisone-modified-release-in-adults-real-world-monitoring-of-longitudinal-outcomes-in-congenital-adrenal-hyperplasia-100643399","NCT07622030","Hydrocortisone Modified-release in Adults: Real-world Monitoring of Longitudinal Outcomes in coNgenital Adrenal hYperplasia","Long-term Real-world Outcomes of Chronotherapy With Modified-release Hydrocortisone in Congenital Adrenal Hyperplasia","HARMONY","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Genetically confirmed diagnosis of 21-hydroxylase deficiency congenital adrenal hyperplasia;\n3. Transition from conventional glucocorticoid therapy to modified-release hydrocortisone according to routine clinical practice;\n4. Stable glucocorticoid and mineralocorticoid therapy before transition;\n5. Ability to understand study procedures and provide informed consent for prospective data collection whenever applicable\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years;\n2. Pregnancy or breastfeeding;\n3. Severe uncontrolled medical or psychiatric illness;\n4. Use of glucocorticoids for indications other than CAH;\n5. Use of drugs interfering with glucocorticoid metabolism;\n6. History of bilateral adrenalectomy",{"count":99,"type":22},"5 Years","Classic congenital adrenal hyperplasia (CAH) is an autosomal recessive genetic disorder caused by a defect in the enzyme cascade regulating adrenal steroidogenesis; in approximately 95% of cases the defect is located in CYP21A2, the gene encoding 21-hydroxylase, and is characterized by defective adrenal steroidogenesis and cortisol deficiency. Due to the loss of physiological cortisol feedback on the hypothalamus and pituitary corticotropic cells, ACTH secretion is increased. This results in the accumulation of 17-hydroxyprogesterone (17OHP) proximal to the enzymatic defect in steroidogenesis, which in turn stimulates overproduction of the adrenal androgen precursor androstenedione and adrenal hyperplasia.\n\nTreatment of CAH is tailored to the patient and disease severity, aiming to replace cortisol and aldosterone deficiencies while controlling androgen excess and avoiding glucocorticoid overtreatment. Immediate-release hydrocortisone administered multiple times daily remains the recommended first-line treatment in growing children, whereas adult patients are frequently treated with hydrocortisone, prednisone, prednisolone or dexamethasone.\n\nHowever, conventional glucocorticoid regimens cannot adequately reproduce the physiological circadian rhythm of cortisol secretion. In physiological conditions, ACTH-driven cortisol secretion follows a clear circadian rhythm characterized by low evening levels, nocturnal increase between 2:00 and 4:00 a.m., a morning peak upon awakening, and progressive decline during daytime.\n\nDual daytime dosing of immediate-release hydrocortisone in CAH can control ACTH-driven adrenal androgen secretion during the day; however, because of its rapid absorption into the bloodstream and short half-life, the evening dose of hydrocortisone cannot adequately suppress the nocturnal ACTH surge and ACTH-driven adrenal androgen overproduction.\n\nConsequently, patients are often exposed to supraphysiological glucocorticoid doses during nighttime hours in an attempt to control morning hyperandrogenism. The disruption of physiological cortisol homeostasis contributes to poor cardiometabolic profile, obesity, insulin resistance, impaired fertility, reduced quality of life, and increased cardiovascular morbidity and mortality observed in patients with CAH.\n\nBone health may also be impaired in patients with CAH because of chronic glucocorticoid exposure and androgen imbalance. Previous studies demonstrated reduced lumbar and femoral bone mineral density and increased fracture risk in both male and female patients.\n\nModified-release hydrocortisone (MR-HC; Efmody®) is a multiparticulate formulation developed to better reproduce physiological cortisol circadian rhythm through chronotherapy. Previous phase II and phase III studies demonstrated improved biochemical control, reduction in androgen excess, lower glucocorticoid exposure, improved fertility outcomes, and sustained long-term efficacy compared with conventional glucocorticoid regimens.\n\nHowever, real-world longitudinal data regarding long-term biochemical, metabolic, cardiovascular, reproductive and skeletal outcomes remain limited, particularly in adult patients transitioning from pediatric to adult endocrine care.\n\nThe present study is a single-center, retrospective and prospective, longitudinal, open-label observational cohort study aimed at evaluating the long-term real-world outcomes of chronotherapy with modified-release hydrocortisone in adult patients with genetically confirmed 21-hydroxylase deficiency CAH.\n\nRetrospective clinical, biochemical and radiological data already available from routine clinical care will be collected from medical records, while prospective observational follow-up will continue according to routine endocrine clinical practice.",[620],"CAH - Congenital Adrenal Hyperplasia",[622,623,624,625],"chronotherapy","hydrocortisone","21-hydroxylase deficiency CAH","outcomes","2026-06-04",{"date":628,"type":55},"2026-06-08",{"date":249,"type":22},{"date":631,"type":22},"2031-07-31",{"name":61,"class":62},{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":638,"acronym":4,"eligibilityCriteria":639,"healthyVolunteers":12,"sex":71,"minAge":19,"maxAge":4,"enrollmentInfo":640,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":642,"conditions":643,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":650,"leadSponsor":652,"locationsCount":63},"100640307","a-study-comparing-single-port-and-multi-port-robot-assisted-surgery-in-patients-with-prostate-or-kidney-renal-cancer-100640307","NCT07610083","A Study Comparing Single-Port and Multi-Port Robot-Assisted Surgery in Patients With Prostate or Kidney (Renal) Cancer","Single-port vs. Multi-port Robot-assisted Surgery for Prostate or Renal Cancer","Inclusion Criteria:\n\n* The participant provides written informed consent\n* Male or female participants who are at least 18 years of age on the day of signing informed consent\n* Men with a diagnosis of prostate or renal cancer and women with a diagnosis of renal cancer\n* Pre-operative imaging performed for staging purposes (i.e. CT scan, PSMA PET) showing no suspicious evidence of distant metastases in prostate or renal cancer patients\n* Suitable for RARP or RAPN.\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years\n* Mental or physical disability that may prevent the patient from satisfying the requirements of the protocol\n* Inability to read and sign the informed consent\n* No available pre-operative staging\n* Contraindication to surgery\n* Presence of distant metastases (M1)",{"count":641,"type":22},376,"This is a prospective single-center observational study comparing single-port (SP) and multi-port (MP) robot-assisted surgery in adult patients undergoing robot-assisted radical prostatectomy (RARP) or robot-assisted partial nephrectomy (RAPN) for prostate or kidney cancer.\n\nConsecutive eligible patients will be managed according to routine clinical practice and assigned to SP or MP surgery based on predefined clinical and anatomical criteria, surgeon assessment, patient and tumor characteristics, platform availability, and surgical expertise. No randomization will be performed.\n\nThe study aims to compare perioperative outcomes between the two surgical approaches, with length of hospital stay (LOS) as the primary endpoint. Secondary endpoints include intraoperative outcomes (operative time, estimated blood loss, and intraoperative complications), postoperative recovery, pain, postoperative complications, readmission rates, positive surgical margins, and hospital costs.\n\nFunctional and patient-reported outcomes will also be evaluated, including urinary continence, sexual function, health-related quality of life, renal function after partial nephrectomy, decision regret, and cosmetic satisfaction.",[644,645],"Prostate Cancer","Renal Cancer","2026-05-20",{"date":648,"type":55},"2026-05-27",{"date":507,"type":22},{"date":651,"type":22},"2030-06",{"name":61,"class":62},""]